Literature DB >> 16937012

Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.

Giovanni Antonini1, Maria Cristina Cox, Enrico Montefusco, Antonella Ferrari, Esmeralda Conte, Stefania Morino, Pamela Latino, Guido Trasimeni, Bruno Monarca.   

Abstract

A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16937012     DOI： 10.1007/s11060-006-9217-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  11 in total

1.  Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors:  U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.

Authors:  A Harjunpää; T Wiklund; J Collan; R Janes; J Rosenberg; D Lee; A Grillo-López; S Meri
Journal:  Leuk Lymphoma       Date:  2001-08

3.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Authors:  Holger Schulz; Hendrik Pels; Ingo Schmidt-Wolf; Ulrich Zeelen; Ulrich Germing; Andreas Engert
Journal:  Haematologica       Date:  2004-06       Impact factor: 9.941

4.  Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.

Authors:  Naoko Watanabe; Takayuki Takahashi; Naoshi Sugimoto; Yasuhiro Tanaka; Masayuki Kurata; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Kohji Nasu
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

5.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

Authors:  K van Besien; C S Ha; S Murphy; P McLaughlin; A Rodriguez; K Amin; A Forman; J Romaguera; F Hagemeister; A Younes; C Bachier; A Sarris; K S Sobocinski; J D Cox; F Cabanillas
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

Review 6.  Recent advances in primary CNS lymphoma.

Authors:  Khê Hoang-Xuan; Sophie Camilleri-Broët; Carole Soussain
Journal:  Curr Opin Oncol       Date:  2004-11       Impact factor: 3.645

7.  Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.

Authors:  H Pels; H Schulz; O Manzke; E Hom; A Thall; A Engert
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

Authors:  Upendra Hegde; Armando Filie; Richard F Little; John E Janik; Nicole Grant; Seth M Steinberg; Kieron Dunleavy; Elaine S Jaffe; Andrea Abati; Maryalice Stetler-Stevenson; Wyndham H Wilson
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

Review 9.  Primary central nervous system lymphoma.

Authors:  H A Fine; R J Mayer
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

10.  Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.

Authors:  James L Rubenstein; Dan Combs; Jay Rosenberg; Arthur Levy; Michael McDermott; Lloyd Damon; Robert Ignoffo; Kenneth Aldape; Arthur Shen; Dana Lee; Antonio Grillo-Lopez; Marc A Shuman
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113
View more
  12 in total

1.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

2.  Treatment and prophylaxis of hematologic malignancy in the central nervous system.

Authors:  Seema Nagpal; Lawrence Recht
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

3.  Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab.

Authors:  Bing Cao; Xiaoyan Zhou; Dongmei Ji; Junning Cao; Ye Guo; Qunling Zhang; Xianghua Wu; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou; Xiaonan Hong
Journal:  Oncol Lett       Date:  2012-06-13       Impact factor: 2.967

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

5.  Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.

Authors:  Constanza Maximiano Alonso; Antonio Carlos Sánchez Ruiz; Blanca Cantos Sánchez de Ibargüen; Miriam Méndez García; Isabel S Ronco; Mariano Provencio Pulla
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

6.  Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma.

Authors:  Luis Villela; Mauricio García; Rocío Caballero; José R Borbolla-Escoboza; Javier Bolaños-Meade
Journal:  Anticancer Drugs       Date:  2008-10       Impact factor: 2.248

7.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

8.  Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Authors:  James L Rubenstein; Jing Li; Lingjing Chen; Ranjana Advani; Jan Drappatz; Elizabeth Gerstner; Tracy Batchelor; Hendrikus Krouwer; James Hwang; Glenna Auerback; Cigall Kadoch; Clifford Lowell; Pamela Munster; Soonmee Cha; Marc A Shuman; Lloyd E Damon
Journal:  Blood       Date:  2012-11-29       Impact factor: 22.113

9.  Acute painful lumbosacral paresthesia after intrathecal rituximab.

Authors:  J E C Bromberg; J K Doorduijn; J W Baars; G W van Imhoff; R Enting; M J van den Bent
Journal:  J Neurol       Date:  2011-08-10       Impact factor: 4.849

10.  Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.

Authors:  Lore Marretta; H Stocker; D Drauz; M Mueller; A Masuhr; S Dieckmann; V Wong; A Koch; A Grueneisen; K Arastéh; R Weiss
Journal:  Eur J Med Res       Date:  2011-05-12       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.